Skip to the answer

Levetiracetam

Levetiracetam is an antiseizure (antiepileptic) medicine used to treat or add on to treatment for several types of seizures in epilepsy, and it comes as tablets, extended-release tablets, oral solution and an intravenous injection.

Brand names Elepsia XRKeppraKeppra XRSpritamElepsia +4 more
Drug class Decreased Central Nervous System Disorganized Electrical Activity
Rx Forms 4
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026 Content updated Oct 2, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 141 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

✓No current FDA shortage listed · checked Oct 5, 2026 🚨Class I recall on record
Other forms & routes:
Injection
Levetiracetam at a glance The quick version — the full detail is in the Patient Information Guide below.
Dr. Brian Staiger, PharmD, BCPS
The Pharmacist’s Take By · Clinical pharmacist · Written

Levetiracetam (Keppra) is one of the most widely used antiseizure medicines, on the market since about 1999 and available generically, prescribed for partial-onset seizures (seizures that start in one area of the brain) and added to other treatment for some generalized seizures; it seems to work by binding SV2A, a nerve-cell protein that controls how chemical messengers are released. Most people tolerate it well, with sleepiness, tiredness and dizziness the usual complaints, mostly early on. The thing to watch is mood and behavior, since irritability, aggression, depression or suicidal thoughts can appear, more often in children. Report any rash, and never stop it suddenly, because withdrawal seizures can follow.

Clinical pearls

  • In studies it did not change how oral contraceptives or warfarin work, unlike several older seizure medicines.
  • Swallow Keppra XR and other extended-release tablets whole, never crushed or split, and take them once daily.
  • Because the kidneys clear it, kidney disease, dialysis and older age can all mean a lower or adjusted dose.
  • Blood levels can drop during pregnancy, especially the third trimester, so tell your prescriber early if you become pregnant.
How we write & review this content — our editorial policy →
How you get itPrescription only
Comes asTablet, Injection, Extended-release tablet +1
Earliest FDA record1999
Companies listing it with the FDA84
FDA label last updatedJul 1, 2025
FDA’s strongest warning (boxed)None on the label

Patient information guide A plain-language walkthrough of Levetiracetam, written from its FDA label.

What Levetiracetam is used for

▾

Levetiracetam is used for several seizure types in epilepsy. Approvals vary by product.

  • Partial-onset seizures: Keppra, Roweepra and levetiracetam oral solution and injection products for ages 1 month and older; Spritam and tablets for oral suspension for ages 4 and older weighing over 20 kg.
  • Add-on for partial-onset seizures: some generic levetiracetam tablets for ages 4 and older, and Elepsia XR for ages 12 and older.
  • Extended-release products: Keppra XR and Levetiracetam ER for partial-onset seizures in ages 12 and older.
  • Myoclonic seizures in juvenile myoclonic epilepsy, as add-on therapy, ages 12 and older.
  • Primary generalized tonic-clonic seizures in idiopathic generalized epilepsy, as add-on therapy, ages 6 and older.
  • Levetiracetam in Sodium Chloride Injection: add-on therapy in adults 16 and older when oral use is temporarily not feasible.
  • Injections are for intravenous use when oral administration is temporarily not feasible.

How Levetiracetam works

▾

The exact way levetiracetam works is unknown. It binds to SV2A, a protein on nerve-cell vesicles involved in releasing chemical messengers in the brain. This binding may help explain its antiseizure effect.

Levetiracetam dosage

▾

Dosing depends on the product and age. Tablets and oral solution are usually taken twice daily. Extended-release tablets are taken once daily and swallowed whole. Doses are typically increased gradually every couple of weeks.

  • Children weighing 20 kg or less should use the oral solution, measured with a calibrated device.
  • Spritam dissolves in the mouth or in a little liquid.
  • Injection is given into a vein by a healthcare team, usually over 15 minutes.

Follow your prescriber and product label, and ask your pharmacist if you miss a dose.

Dosing details from the FDA-approved label

From the Levetiracetam prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.

  • Partial-Onset Seizures, Adults 16 Years and Older (monotherapy or adjunctive)
    • 500 mg twice daily
    • Increase by 500 mg twice daily every 2 weeks to a recommended dose of 1500 mg twice daily
    • Maximum: 3000 mg/day; no evidence that doses greater than 3000 mg/day confer additional benefit
    • Dose adjustment recommended based on estimated creatinine clearance in adults with impaired renal function
  • Partial-Onset Seizures, Pediatric Patients 1 Month to < 6 Months
    • 7 mg/kg twice daily
    • Increase by 7 mg/kg twice daily every 2 weeks to recommended dose of 21 mg/kg twice daily
    • Use the oral solution with a calibrated measuring device (not a household teaspoon or tablespoon); weight-based dosing
  • Partial-Onset Seizures, Pediatric Patients 6 Months to < 4 Years
    • 10 mg/kg twice daily
    • Increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 25 mg/kg twice daily
    • If a patient cannot tolerate a daily dose of 50 mg/kg, the daily dose may be reduced
  • Partial-Onset Seizures, Pediatric Patients 4 Years to < 16 Years
    • 10 mg/kg twice daily
    • Increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily
    • Maximum: 3000 mg/day
    • If a patient cannot tolerate a daily dose of 60 mg/kg, the daily dose may be reduced
  • Partial-Onset Seizures, Pediatric Patients weighing 20 to 40 kg (tablets)
    • Initiate with 500 mg daily given as 250 mg twice daily
    • Increase the daily dose every 2 weeks by increments of 500 mg
    • Maximum: 1500 mg daily (750 mg twice daily)
    • Tablets swallowed whole, not chewed or crushed
  • Partial-Onset Seizures, Pediatric Patients weighing more than 40 kg (tablets)
    • Initiate with 1000 mg/day given as 500 mg twice daily
    • Increase the daily dose every 2 weeks by increments of 1000 mg/day
    • Maximum: 3000 mg daily (1500 mg twice daily)
    • Tablets swallowed whole, not chewed or crushed
  • Myoclonic Seizures in Adults and Pediatric Patients 12 Years and Older (Juvenile Myoclonic Epilepsy)
    • 500 mg twice daily
    • Increase by 1000 mg/day every 2 weeks to recommended dose of 1500 mg twice daily (3000 mg/day)
    • Effectiveness of doses lower than 3000 mg/day has not been studied
  • Primary Generalized Tonic-Clonic Seizures, Adults 16 Years and Older
    • 500 mg twice daily
    • Increase by 1000 mg/day every 2 weeks to recommended daily dose of 3000 mg (1500 mg twice daily)
    • Effectiveness of doses lower than 3000 mg/day has not been adequately studied
  • Primary Generalized Tonic-Clonic Seizures, Pediatric Patients 6 Years to < 16 Years
    • 10 mg/kg twice daily, increase in increments of 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily
    • Use weight-based dosing with oral solution for body weight ≤ 20 kg
Read the label’s full dosing text

2 DOSAGE & ADMINISTRATION Use the oral solution for pediatric patients with body weight ≤ 20 kg (2.1) For pediatric patients, use weight-based dosing for the oral solution with a calibrated measuring device (not a household teaspoon or tablespoon) (2.1) Partial-Onset Seizures (Monotherapy or Adjunctive therapy) 1 Month to < 6 Months: 7 mg/kg twice daily; increase by 7 mg/kg twice daily every 2 weeks to recommended dose of 21 mg/kg twice daily (2.2) 6 Months to < 4 Years: 10 mg/kg twice daily; increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 25 mg/kg twice daily (2.2) 4 Years to < 16 Years: 10 mg/kg twice daily; increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily (2.2) Adults 16 Years and Older: 500 mg twice daily; increase by 500 mg twice daily every 2 weeks to a recommended dose of 1500 mg twice daily (2.2) Myoclonic Seizures in Adults and Pediatric Patients 12 Years and Older 500 mg twice daily; increase by 500 mg twice daily every 2 weeks to recommended dose of 1500 mg twice daily (2.3) . Primary Generalized Tonic-Clonic Seizures 6 Years to < 16 Years: 10 mg/kg twice daily, increase in increments of 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily (2.4) Adults 16 Years and Older: 500 mg twice daily, increase by 500 mg twice daily every 2 weeks to recommended dose of 1500 mg twice daily (2.4) Adult Patients with Impaired Renal Function Dose adjustment is recommended, based on the patient’s estimated creatinine clearance (2.5, 8.6) 2.1 Important Administration Instructions Levetiracetam oral solution is given orally with or without food. The levetiracetam oral solution dosing regimen depends on the indication, age group, dosage form (oral solution), and renal function. Prescribe the oral solution for pediatric patients with body weight ≤ 20 kg. Prescribe the oral solution for pediatric patients with body weight above 20 kg. When using the oral solution in pediatric patients, dosing is weight-based (mg per kg) using a calibrated measuring device (not a household teaspoon or tablespoon). 2.2 Dosing for Partial-Onset Seizures The recommended dosing for monotherapy and adjunctive therapy is the same; as outlined below. Adults 16 Years of Age and Older Initiate treatment with a daily dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily).

Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →

Levetiracetam side effects

▾

Most side effects are mild and often show up in the first weeks.

Common side effects

  • Sleepiness (somnolence)
  • Weakness or tiredness (asthenia, fatigue)
  • Dizziness
  • Infection
  • Headache
  • In children: aggression, irritability, nasal congestion, decreased appetite

When to get medical help

  • Call your doctor right away if you have new or worsening depression, suicidal thoughts, or unusual mood or behavior changes.
  • Get help if you notice psychotic symptoms, aggression, or severe irritability.
  • Seek emergency care for swelling of the face, lips or throat, or trouble breathing (angioedema or anaphylaxis).
  • Tell your doctor at the first sign of a rash, as serious skin reactions can occur.
  • Get medical help for fever, rash and signs of multiorgan problems (DRESS).
  • Report poor coordination, trouble walking, or unsteadiness.
  • Do not stop suddenly, since withdrawal seizures can occur.

Levetiracetam warnings and precautions

▾
  • Behavior and mood changes: aggression, irritability, psychosis and suicidal thoughts can occur, and are more common in children.
  • Sleepiness and coordination problems: avoid driving or machinery until you know how it affects you.
  • Serious skin reactions and DRESS: stop and call your doctor at the first sign of rash.
  • Allergic reactions: anaphylaxis and angioedema have occurred.
  • Withdrawal seizures: do not stop suddenly; it must be tapered.

Levetiracetam interactions

▾

Levetiracetam has few drug interactions.

  • Other seizure medicines (phenytoin, valproate, carbamazepine, lamotrigine and others): no effect on each other’s levels.
  • Birth control pills: effectiveness unlikely to be impaired.
  • Digoxin and warfarin: no effect on their action in studies.
  • Probenecid: raises a breakdown product of levetiracetam but not levetiracetam itself.

Interactions listed in the FDA-approved label

From the Levetiracetam prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Phenytoin: Levetiracetam had no effect on the pharmacokinetics of phenytoin, and phenytoin did not affect levetiracetam pharmacokinetics.
  • Valproate: Levetiracetam did not alter the pharmacokinetics of valproate, and valproate did not modify levetiracetam absorption, clearance or urinary excretion.
  • Other Antiepileptic Drugs (carbamazepine, gabapentin, lamotrigine, phenobarbital, primidone): Levetiracetam does not influence plasma concentrations of other AEDs and these AEDs do not influence levetiracetam pharmacokinetics.
  • Enzyme-inducing AEDs in pediatric patients: About a 22% increase of apparent total body clearance of levetiracetam when co-administered. Dose adjustment is not recommended.
  • Oral contraceptives: Levetiracetam did not influence the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and levonorgestrel, so impairment of contraceptive efficacy is unlikely.
  • Digoxin: Levetiracetam did not influence the pharmacokinetics and pharmacodynamics (ECG) of digoxin, and digoxin did not influence levetiracetam.
  • Warfarin: Levetiracetam did not influence the pharmacokinetics of R and S warfarin or prothrombin time, and warfarin did not affect levetiracetam.
  • Probenecid: Probenecid did not change levetiracetam pharmacokinetics, but Css max of the metabolite ucb L057 approximately doubled and its renal clearance decreased 60%.
Read the label’s full interactions text

Drug Interactions In vitro data on metabolic interactions indicate that levetiracetam is unlikely to produce, or be subject to, pharmacokinetic interactions. Levetiracetam and its major metabolite, at concentrations well above C max levels achieved within the therapeutic dose range, are neither inhibitors of, nor high affinity substrates for, human liver cytochrome P450 isoforms, epoxide hydrolase or UDP-glucuronidation enzymes. In addition, levetiracetam does not affect the in vitro glucuronidation of valproic acid. Potential pharmacokinetic interactions of or with levetiracetam were assessed in clinical pharmacokinetic studies (phenytoin, valproate, warfarin, digoxin, oral contraceptive, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients. Phenytoin Levetiracetam (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy. Pharmacokinetics of levetiracetam were also not affected by phenytoin. Valproate Levetiracetam (1500 mg twice daily) did not alter the pharmacokinetics of valproate in healthy volunteers. Valproate 500 mg twice daily did not modify the rate or extent of levetiracetam absorption or its plasma clearance or urinary excretion. There also was no effect on exposure to and the excretion of the primary metabolite, ucb L057. Other Antiepileptic Drugs Potential drug interactions between levetiracetam and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies. These data indicate that levetiracetam does not influence the plasma concentration of other AEDs and that these AEDs do not influence the pharmacokinetics of levetiracetam.

Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

🌿105 supplements and herbs with documented Levetiracetam interactions, ranked by severity Check Levetiracetam against a supplement or herb →

Before taking Levetiracetam

▾
  • Do not use if you are allergic to levetiracetam.
  • Kidney problems may require dose adjustment, including extra doses after dialysis.
  • Older adults may have reduced kidney function.
  • Pregnancy can lower drug levels; a pregnancy registry exists.
  • It passes into breast milk.
  • Spritam and tablets for oral suspension are not recommended for children 20 kg or less.

Levetiracetam overdose

▾

Overdose can cause sleepiness, agitation, aggression, reduced alertness, slowed breathing and coma. There is no specific antidote. Contact a Poison Control Center or emergency services; supportive care is given and dialysis may help remove the drug.

What Levetiracetam does in the body

▾

In a study of healthy volunteers, levetiracetam injection showed no evidence of significant QTc prolongation, a heart rhythm measure.

How your body processes Levetiracetam

▾

Levetiracetam is rapidly and almost completely absorbed when taken by mouth. Injection and tablets are bioequivalent, and a 15-minute infusion gives equivalent exposure to the same oral dose. Its levels in the body are predictable and it is not significantly protein-bound. Kidneys clear much of it, so kidney problems slow clearance.

How to store Levetiracetam

▾

Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) .

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

105

Supplements & herbs that interact with Levetiracetam

105 supplements and herbal products have documented interactions with Levetiracetam in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.

Severity mix
  • Major · 7
  • Moderate · 82
  • Minor · 16
1,4-BUTANEDIOL Major ACTIVATED CHARCOAL Major BEER Major GAMMA-HYDROXYBUTYRATE (GHB) Major KAVA Major L-TRYPTOPHAN Major WINE Major 5-HTP Moderate +97 more
Every supplement checked against Levetiracetam — ranked by severity The full interaction hub: 7 major · 82 moderate · 16 minor · every one linked to its full report. Check Levetiracetam against your exact supplements

Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

1

Nutrient depletion considerations

Levetiracetam has been associated with lower levels of 1 nutrient in the clinical literature. This does not mean a deficiency will occur — it means these may be worth discussing with your pharmacist or healthcare provider, especially with long-term use.

VITAMIN K Insignificant Depletion
See the full Levetiracetam nutrient depletion report

Educational information from a licensed clinical database (Natural Medicines) — not medical advice. Do not start or stop medications or supplements without professional guidance.

Levetiracetam: pharmacist answers to common questions

Quick, plain-English answers to the questions patients ask most about Levetiracetam — the kind of thing our pharmacy team would talk through with you at the counter.

What is levetiracetam used for?

▾
It treats seizures in epilepsy. Depending on the product, that means partial-onset seizures, and as add-on therapy, myoclonic seizures in juvenile myoclonic epilepsy and primary generalized tonic-clonic seizures. Your product and age determine which applies.

How should I take it?

▾
Follow your prescriber and label. Tablets and solution are usually twice daily, while extended-release tablets are once daily and must be swallowed whole. Use a calibrated device for liquid, not a kitchen spoon.

What side effects should I expect?

▾
Sleepiness, tiredness, dizziness and headache are common, especially early on. Children may become irritable or aggressive. Avoid driving until you know how it affects you.

When should I call my doctor?

▾
Call right away for new or worsening depression, suicidal thoughts, unusual behavior, a rash, swelling of the face or throat, or trouble walking. Get emergency help for trouble breathing.

Can I stop it if I feel better?

▾
No. Stopping suddenly can trigger withdrawal seizures, so it must be reduced gradually under your prescriber’s guidance.

Is it safe in pregnancy?

▾
Long experience hasn’t linked it to major birth defects or miscarriage, but animal studies showed harm. Blood levels can drop during pregnancy, so talk with your doctor about monitoring and the pregnancy registry.

Is Levetiracetam available over the counter?

▾
No. Levetiracetam is a prescription medicine: every Levetiracetam product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was Levetiracetam first available?

▾
The earliest FDA record we hold for Levetiracetam is from 1999: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when Levetiracetam was first used.

Who makes Levetiracetam?

▾
84 companies currently list Levetiracetam products in the FDA's NDC Directory, including A-S Medication Solutions, Bryant Ranch Prepack, Remedyrepack Inc.. That count includes repackagers and distributors as well as manufacturers (companies that sell only the raw ingredient are not counted), so fewer companies actually make it; the label on your bottle names the one that supplied yours.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

More about Levetiracetam on HelloPharmacist

📊Levetiracetam supplement interactions105 checked — ranked by severity 🌿Drug & Supplement CheckerLevetiracetam vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Levetiracetam NDCs & costs 🅰️Browse Drugs A–ZLook up any medication
Detailed data & references for Levetiracetam Forms & strengths, pricing, billing codes, manufacturers, safety reports and sourcing — the data behind the page. Most people can stop here. Each section below opens on a tap.

Levetiracetam forms and strengths (how it comes)

Levetiracetam is available in 4 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Tablet

By mouth
Brands Keppra Roweepra Spritam
How this form is used
What it may be used for
  • Roweepra tablets are for partial-onset seizures in patients 1 month and older, plus add-on use for myoclonic and primary generalized tonic-clonic seizures at labeled ages.
  • Spritam is for partial-onset seizures in patients 4 and older weighing over 20 kg, plus add-on use for myoclonic and primary generalized tonic-clonic seizures.
Important instructions
  • Spritam disintegrates in the mouth with a sip of liquid; swallow only after it disintegrates and do not swallow it whole.
  • Spritam can be dispersed in a small amount of liquid and taken right away, and partial tablets should not be given.
Available strengths 4 strengths
250 mg 500 mg 750 mg 1000 mg
380 FDA-listed product records ⓘ

Injection

By injection · Into a vein · Iontophoresis
Brands Keppra Levetiracetam in Sodium Chloride
How this form is used
What it may be used for
  • Keppra injection is for intravenous use when oral administration is temporarily not feasible.
  • Levetiracetam in Sodium Chloride Injection is add-on therapy in adults 16 and older when oral use is temporarily not feasible.
Important instructions
  • Keppra injection is for intravenous use only.
  • Levetiracetam in Sodium Chloride Injection is for intravenous infusion only, not diluted first, given over 15 minutes.
Available strengths 8 strengths
5 mg/mL 10 mg/mL 15 mg/mL 100 mg/mL 500 mg/5 mL 500 mg/100 mL
Show 2 more strengths Show fewer strengths
1000 mg/100 mL 1500 mg/100 mL
129 FDA-listed product records ⓘ

Extended-release tablet

By mouth
Brands Elepsia Xr 1000 Mg Elepsia Xr 1500 Mg Keppra
How this form is used
What it may be used for
  • Keppra XR is for partial-onset seizures in patients 12 and older.
  • Elepsia XR is add-on therapy for partial-onset seizures in patients 12 and older.
  • Levetiracetam ER is for partial-onset seizures in patients 12 and older.
Important instructions
  • Keppra XR is taken once daily and swallowed whole, not chewed, broken or crushed.
  • Elepsia XR is taken once daily and swallowed whole; do not split or cut it.
  • Levetiracetam ER is taken once daily and swallowed whole, not chewed, broken or crushed.
Available strengths 4 strengths
500 mg 750 mg 1000 mg 1500 mg
79 FDA-listed product records ⓘ

Oral solution

By mouth
Brands Keppra
How this form is used
What it may be used for
  • Keppra oral solution is for partial-onset seizures in patients 1 month and older, plus add-on use for myoclonic and primary generalized tonic-clonic seizures at labeled ages.
Important instructions
  • Keppra labeling says to use the oral solution for children weighing 20 kg or less.
  • For children, Keppra oral solution is dosed by weight with a calibrated measuring device, not a household spoon.
Available strengths 4 strengths
100 mg/mL 500 mg/5 mL 1000 mg/10 mL 1500 mg/15 mL
66 FDA-listed product records ⓘ

Levetiracetam on the U.S. market: products, makers and brands

How Levetiracetam appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

84 companies list 301 Levetiracetam product records with the FDA, mostly as tablet, injection, extended-release tablet; the earliest marketing or approval year on record is 1999. Brand names on the directory include Elepsia XR, Keppra, Keppra XR and 6 more; the rest are generics.

4
Dose forms ⓘ
84
Labelers (makers, repackagers, distributors)
12
Brand names
301
FDA-listed product records ⓘ
1999
Earliest FDA record ⓘ

FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

Also listed with the FDA, not a patient dose form: Powder (34) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.

A-S Medication Solutions5%
Bryant Ranch Prepack5%
Remedyrepack Inc.4%
Solco Healthcare US, LLC4%
UCB, Inc.3%
Coupler LLC2%
Other makers78%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

How widely Levetiracetam is used (Medicaid data)

A general measure of how commonly Levetiracetam is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Levetiracetam is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

3,055,070
Medicaid prescriptions filled (Q1–Q4 2025)
$110.8M gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Levetiracetam prescribed? Of the 1,601 medications we measure, Levetiracetam ranks #72 by Medicaid prescriptions — more than 96% of them.

Where Levetiracetam ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #72 of 1,601
#67 Hydrochlorothiazide 3,216,975 Rx #68 Hydrocortisone 3,162,599 Rx #69 Divalproex 3,122,967 Rx #70 Tirzepatide injection 3,083,095 Rx #71 Tirzepatide 3,083,095 Rx #72 Levetiracetam 3,055,070 Rx #73 Oxycodone 3,037,434 Rx #74 Clindamycin 3,018,439 Rx #75 Hydrocortisone Topical 2,941,220 Rx #76 Mupirocin 2,929,179 Rx #77 Empagliflozin 2,905,773 Rx

Utilization by Levetiracetam product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

The 500 mg oral tablet is the most-dispensed Levetiracetam product — about 30% of these Medicaid prescriptions.

levetiracetam 500 MG Oral Tablet Most dispensed

918,215 Medicaid prescriptions (Q1–Q4 2025) 30% of Levetiracetam prescriptions shown $21.9M gross reimbursement (before rebates) ≈ $24 per prescription (gross)

Summed across the 27 of 194 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 311289

levetiracetam 100 MG/ML Oral Solution

808,463 Medicaid prescriptions (Q1–Q4 2025) 26% of Levetiracetam prescriptions shown $29.2M gross reimbursement (before rebates) ≈ $36 per prescription (gross)

Summed across the 12 of 121 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 403884

levetiracetam 1000 MG Oral Tablet

571,074 Medicaid prescriptions (Q1–Q4 2025) 19% of Levetiracetam prescriptions shown $24.5M gross reimbursement (before rebates) ≈ $43 per prescription (gross)

Summed across the 16 of 99 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 387003

levetiracetam 750 MG Oral Tablet

460,966 Medicaid prescriptions (Q1–Q4 2025) 15% of Levetiracetam prescriptions shown $14.8M gross reimbursement (before rebates) ≈ $32 per prescription (gross)

Summed across the 23 of 96 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 311290

levetiracetam 250 MG Oral Tablet

117,815 Medicaid prescriptions (Q1–Q4 2025) 4% of Levetiracetam prescriptions shown $2.8M gross reimbursement (before rebates) ≈ $23 per prescription (gross)

Summed across the 22 of 113 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 311288

24 HR levetiracetam 500 MG Extended Release Oral Tablet

89,562 Medicaid prescriptions (Q1–Q4 2025) 3% of Levetiracetam prescriptions shown $9.3M gross reimbursement (before rebates) ≈ $104 per prescription (gross)

Summed across the 7 of 50 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 807832

24 HR levetiracetam 750 MG Extended Release Oral Tablet

65,742 Medicaid prescriptions (Q1–Q4 2025) 2% of Levetiracetam prescriptions shown $6.7M gross reimbursement (before rebates) ≈ $102 per prescription (gross)

Summed across the 8 of 36 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 846378

5 ML levetiracetam 100 MG/ML Injection

16,644 Medicaid prescriptions (Q1–Q4 2025) <1% of Levetiracetam prescriptions shown $694,270 gross reimbursement (before rebates) ≈ $42 per prescription (gross)

Summed across the 19 of 50 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 647121

100 ML levetiracetam 10 MG/ML Injection

4,698 Medicaid prescriptions (Q1–Q4 2025) <1% of Levetiracetam prescriptions shown $155,683 gross reimbursement (before rebates) ≈ $33 per prescription (gross)

Summed across the 9 of 30 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1193358

100 ML levetiracetam 15 MG/ML Injection

833 Medicaid prescriptions (Q1–Q4 2025) <1% of Levetiracetam prescriptions shown $45,357 gross reimbursement (before rebates) ≈ $54 per prescription (gross)

Summed across the 8 of 28 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1193360

100 ML levetiracetam 5 MG/ML Injection

456 Medicaid prescriptions (Q1–Q4 2025) <1% of Levetiracetam prescriptions shown $22,001 gross reimbursement (before rebates) ≈ $48 per prescription (gross)

Summed across the 7 of 30 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1193362

levetiracetam 500 MG Tablet for Oral Suspension

368 Medicaid prescriptions (Q1–Q4 2025) <1% of Levetiracetam prescriptions shown $327,762 gross reimbursement (before rebates) ≈ $891 per prescription (gross)

Summed across the 1 of 5 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1736048

levetiracetam 1000 MG Tablet for Oral Suspension

129 Medicaid prescriptions (Q1–Q4 2025) <1% of Levetiracetam prescriptions shown $114,373 gross reimbursement (before rebates) ≈ $887 per prescription (gross)

Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1736037

levetiracetam 250 MG Tablet for Oral Suspension

61 Medicaid prescriptions (Q1–Q4 2025) <1% of Levetiracetam prescriptions shown $82,423 gross reimbursement (before rebates) ≈ $1,351 per prescription (gross)

Summed across the 1 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1736045

levetiracetam 750 MG Tablet for Oral Suspension

44 Medicaid prescriptions (Q1–Q4 2025) <1% of Levetiracetam prescriptions shown $36,218 gross reimbursement (before rebates) ≈ $823 per prescription (gross)

Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1736051

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Levetiracetam, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 162 of 862 listed Levetiracetam NDCs with Medicaid activity.

Compare Levetiracetam products

A representative set of FDA-listed product records for Levetiracetam — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 101 of 301 products — FDA National Drug Code Directory. See every product, package size and price: browse all 301 Levetiracetam NDCs →

Levetiracetam recall history

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list one Levetiracetam recall since July 2021. It is still ongoing. A recall names specific lots from one company, so check the lot number on your own bottle rather than assuming every product is affected; your pharmacist can check whether your supply came from an affected lot.

Ongoing Class I Mar 13, 2025 · Dr. Reddy's Laboratories, Inc.
LABELING: LABEL MIX-UP: The infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000…
  • Levetiracetam 0.75% in Sodium Chloride Injection 1,000 mg/100 mL (10 mg/mL), 1 x 100mL, Rx Only, Manufactured by: Gland Pharma Limited, Hyderabad, - 500 043 INDIA, Distributor: Dr. Reddy's Laboratori… Lots: Lot: A1540076, Exp 08/31/2026 FDA record D-0365-2025 →

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Levetiracetam RxCUI 114477 5 dose forms · 18 strengths
  3. Dose form (SCDF) Oral Solution RxCUI 406121 In current FDA listings
    Clinical drug / strength (SCD) 100 MG/ML RxCUI 403884
  4. Dose form (SCDF) Oral Tablet RxCUI 374617 In current FDA listings
    Clinical drug / strength (SCD) 250 MG RxCUI 311288 500 MG RxCUI 311289 750 MG RxCUI 311290 1000 MG RxCUI 387003
  5. Dose form (SCDF) Tablet for Oral Suspension RxCUI 1869554 In current FDA listings
    Clinical drug / strength (SCD) 250 MG RxCUI 1736045 500 MG RxCUI 1736048 750 MG RxCUI 1736051 1000 MG RxCUI 1736037

Look up RxCUI 114477 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

💵 What Levetiracetam costs pharmacies (NADAC benchmark)

The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.

FormStrengthPharmacy acquisition benchmark
Tablet, Film Coated · Oral 500 mg $0.074 per tablet NDC details & price history
Tablet, Film Coated · Oral 1000 mg $0.160 per tablet NDC details & price history
Tablet, Film Coated · Oral 750 mg $0.109 per tablet NDC details & price history
Tablet · Oral 500 mg $0.095 per tablet NDC details & price history
Tablet · Oral 250 mg $0.064 per tablet NDC details & price history
Tablet · Oral 1000 mg $0.194 per tablet NDC details & price history
Tablet · Oral 750 mg $0.137 per tablet NDC details & price history
Solution · Oral 100 mg/mL $0.030 per mL NDC details & price history
Tablet, Film Coated, Extended Release · Oral 500 mg $0.174 per tablet NDC details & price history
Tablet, Film Coated, Extended Release · Oral 750 mg $0.223 per tablet NDC details & price history
Why show this? Your out-of-pocket cost depends on insurance, pharmacy markup, and discounts — but the acquisition benchmark tells you whether the medication itself is inexpensive or costly, which strengths cost more per dose, and whether a cash-price quote is in a reasonable range. Each row links to the NDC-level record with its full price history.

Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.

Levetiracetam brand names

Levetiracetam is sold under 9 brand names in the FDA directory — Elepsia XR, Keppra, Keppra XR, Spritam and others. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.

Elepsia XR Keppra Keppra XR Spritam Elepsia Roweepra Levetiracetam in Sodium Chloride Elepsia Xr 1000 Mg Elepsia Xr 1500 Mg

Who makes Levetiracetam: manufacturers and labelers

84 companies list Levetiracetam products with the FDA. By number of product records, the largest are A-S Medication Solutions, Bryant Ranch Prepack, Remedyrepack Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

A-S Medication Solutions 14 Bryant Ranch Prepack 14 Remedyrepack Inc. 13 Solco Healthcare US, LLC 11 UCB, Inc. 8 Coupler LLC 7 BluePoint Laboratories 6 Cardinal Health 107, LLC 6 Dr.Reddy's Laboratories Inc 6 Lupin Pharmaceuticals, Inc. 6 Novadoz Pharmaceuticals LLC 6 ScieGen Pharmaceuticals, Inc. 6 Torrent Pharmaceuticals Limited 6 American Health Packaging 5 Amneal Pharmaceuticals LLC 5 Aurobindo Pharma Limited 5 Camber Pharmaceuticals, Inc. 5 Hikma Pharmaceuticals USA Inc. 5 Major Pharmaceuticals 5 NorthStar RxLLC 5 Asclemed Usa Inc. 4 Aprecia Pharmaceuticals, LLC 4 Ascend Laboratories, LLC 4 Baxter Healthcare Corporation 4

…and 60 more on the FDA NDC directory.

Levetiracetam drug class (RxNorm)

Levetiracetam belongs to the Other antiepileptics class.

Drug family (ATC) Other antiepileptics

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

Sources for this Levetiracetam page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective Jul 1, 2025
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Levetiracetam.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Levetiracetam after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
141
Finished products in the current FDA directory
301
Companies listing them (makers, repackagers, distributors)
84
FDA labeler codes behind them ⓘ
90
Linked representative label ⓘ
Prasco Laboratories
Linked label effective
Jul 1, 2025
Composite sections available
23
Linked SPL Set ID
dd175fa3-1d7a-4542-affd-988ac5bba1db
Linked SPL Document ID
265f6517-11c1-4af8-9871-ef7fdde464e6
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Prasco Laboratories is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →